Is pramlintide (Symlin) FDA approved for the management of obesity?

Updated: Jun 09, 2021
  • Author: Osama Hamdy, MD, PhD; Chief Editor: Romesh Khardori, MD, PhD, FACP  more...
  • Print

The diabetes drug pramlintide (Symlin), which is a synthetic analogue of the pancreatic hormone amylin, does not have an FDA indication for obesity management. However, this drug is clearly associated with variable weight loss in people with type 1 or 2 diabetes, while improving overall glycemic control. Higher doses (240 mcg before main meals) than those approved for the management of type 2 diabetes (60-120 mcg before main meals) have produced modest weight loss in obese or overweight patients with and without diabetes. [174]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!